Cullinan Therapeutics (CGEM) vs Iambic Therapeutics (IAM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Iambic Therapeutics is the larger company by market cap ($621.4 million vs $577.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEM | IAM |
|---|---|---|
| Share price | $8.89 | $13.11 |
| Market cap | $577.15M | $621.42M |
| 1-day change | -1.98% | -8.06% |
| YTD return | -14.11% | — |
| 1-year return | -6.12% | — |
| 5-year return | -51.21% | — |
| EPS (TTM) | $-3.09 | $-2.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-219.88M | — |
| 52-week high | $23.19 | $25.00 |
| 52-week low | $8.47 | $9.60 |
| Distance from 52-week high | -61.66% | -47.56% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +285.49% | +107.86% |
| Average volume | 997.14K | 714.92K |
| Shares outstanding | 64.92M | 47.40M |
| Employees | 109 | 171 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Cullinan Therapeutics
CGEM stock →Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
About Iambic Therapeutics
IAM stock →Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 171 employees
CGEM vs IAM FAQ
Which is bigger, Cullinan Therapeutics or Iambic Therapeutics?
Iambic Therapeutics (IAM) is larger, with a market capitalization of $621.42M compared with $577.15M for Cullinan Therapeutics (CGEM).
Are Cullinan Therapeutics and Iambic Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.